Datum Källa Rubrik Typ Alternativ
2024-06-11 Nanexa First patient dosed in Nanexa's Phase I trial of NEX-22 in type 2 diabetes Pressreleaser Ladda ner | Visa Stäng
2024-06-11 Nanexa Första patient doserad i Nanexas fas I-studie med NEX-22 inom typ 2-diabetes Pressreleaser Ladda ner | Visa Stäng
2024-05-15 Nanexa Kommuniké från årsstämma i Nanexa AB Pressreleaser Ladda ner | Visa Stäng
2024-05-15 Nanexa Bulletin from Nanexa’s Annual General Meeting Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 15 May 2024 | Nanexa

Bulletin from Nanexa’s Annual General Meeting

The Annual General Meeting (AGM) of Nanexa AB (publ) has been held on May 15, 2024, at which meeting submitted proposals were passed. The complete proposals for resolutions are set out in the AGM notice.

The income statement and balance sheet were adopted, together with the board of directors’ proposal for allocation of the company’s result. The board of directors and CEO were discharged from liability for the financial year 2023.

Göran Ando, Richard Davis, Jakob Dynnes Hansen, Eva Nilsagård and Birgit Stattin Norinder were re-elected, and Hanna Tilus was elected, as members of the board. Göran Ando was re-elected as chairman of the board.

The AGM voted on directors’ fees in accordance with the nomination committee’s proposal as follows:

Remuneration shall be paid with SEK 260,000 for the chairman and with SEK 130,000 to other board members not employed by the company. Furthermore, SEK 100,000 shall be paid to the chairman of the audit committee and SEK 50,000 to each other member of the audit committee.

The registered accounting firm Öhrlings PricewaterhouseCoopers AB was appointed auditor. Niclas Bergenmo will continue as auditor in charge.

The proposal from the nomination committee regarding the establishment of a nomination committee and instructions to the nomination committee were approved.

In accordance with the board of directors’ proposal, the AGM resolved on changes to the provisions of the articles of association concerning the limits for the company’s share capital and number of shares.

The AGM further resolved to adopt the board of directors’ proposals regarding authorizations for the board to decide on rights issues and directed issues.

2024-05-15 Nanexa Nanexa receives approval for NEX-22 clinical study Pressreleaser Ladda ner | Visa Stäng
2024-05-15 Nanexa Nanexa erhåller godkännande för klinisk studie med NEX-22 Pressreleaser Ladda ner | Visa Stäng
2024-05-10 Redeye Redeye: Nanexa Q1 2024 - Insightful capital markets day Pressreleaser Ladda ner | Visa Stäng
2024-05-10 Emergers Emergers: Equity Research | NANEXA: Insights from CMD underscore near- to mid-term opportunities with significant potential Pressreleaser Ladda ner | Visa Stäng
2024-05-03 Nanexa Nanexa publishes interim report for January-March 2024 Rapporter Ladda ner | Visa Stäng
2024-05-03 Nanexa Nanexa publicerar delårsrapport för januari-mars 2024 Rapporter Ladda ner | Visa Stäng
2024-04-30 Nanexa Invitation to comment on Nanexa's Q1 report 2024 Pressreleaser Ladda ner | Visa Stäng
2024-04-30 Nanexa Inbjudan till kommentar av Nanexas Q1-rapport 2024 Pressreleaser Ladda ner | Visa Stäng
2024-04-29 Nanexa Nanexa invites to Capital Markets Day on May 7 Pressreleaser Ladda ner | Visa Stäng
2024-04-29 Nanexa Nanexa bjuder in till kapitalmarknadsdag 7 maj Pressreleaser Ladda ner | Visa Stäng
2024-04-16 Nanexa Godkännandet av klinisk prövningsansökan för NEX-22-studien försenas Pressreleaser Ladda ner | Visa Stäng
2024-04-16 Nanexa Approval of clinical trial application for NEX-22 study delayed Pressreleaser Ladda ner | Visa Stäng
2024-04-15 Nanexa Notice of annual general meeting in Nanexa AB (publ) Pressreleaser Ladda ner | Visa Stäng
2024-04-15 Nanexa Kallelse till årsstämma Nanexa AB (publ) Pressreleaser Ladda ner | Visa Stäng
2024-03-27 Nanexa Nanexa publicerar årsredovisning för 2023 Rapporter Ladda ner | Visa Stäng
2024-03-27 Nanexa Nanexa publishes annual report for 2023 Rapporter Ladda ner | Visa Stäng
2024-02-22 Redeye Redeye: Nanexa - NEX-22, partner projects, and Novo Nordisk evaluation prioritized Pressreleaser Ladda ner | Visa Stäng
2024-02-22 Emergers Emergers: Equity Research | NANEXA: Focus on dual GLP-1 opportunities and the partner projects Pressreleaser Ladda ner | Visa Stäng
2024-02-21 Nanexa Nanexa publishes year-end report and Q4 report 2023 Rapporter Ladda ner | Visa Stäng
2024-02-21 Nanexa Nanexa publicerar bokslutskommuniké och Q4-rapport 2023 Rapporter Ladda ner | Visa Stäng
2024-02-20 Nanexa Invitation to presentation of Nanexa's year-end report and Q4 report 2023 Pressreleaser Ladda ner | Visa Stäng
2024-02-20 Nanexa Inbjudan till presentation av Nanexas bokslutskommuniké och Q4-rapport 2023 Pressreleaser Ladda ner | Visa Stäng
2023-12-21 Emergers Emergers: Equity Research | NANEXA: Lining up to make Nanexa (close to) a pure GLP-1 play Pressreleaser Ladda ner | Visa Stäng
2023-12-20 Nanexa Nanexa’s clinical trial application for NEX-22 Phase I study assessed by EMA Pressreleaser Ladda ner | Visa Stäng
2023-12-20 Nanexa Nanexa optimizes business operations through tactical priorities Pressreleaser Ladda ner | Visa Stäng
2023-12-20 Nanexa Nanexas kliniska prövningsansökan för NEX-22 fas I-studie emottagen av EMA Pressreleaser Ladda ner | Visa Stäng
2023-12-20 Nanexa Nanexa optimerar affärsverksamheten genom taktiska prioriteringar Pressreleaser Ladda ner | Visa Stäng
2023-11-30 Nanexa Nanexa changes Certified Adviser to Carnegie Investment Bank AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-11-30 Nanexa Nanexa byter Certified Adviser till Carnegie Investment Bank AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-11-29 Nanexa Nanexa tecknar utvärderingsavtal med ett stort globalt läkemedelsbolag Pressreleaser Ladda ner | Visa Stäng
2023-11-29 Nanexa Nanexa signs evaluation agreement with a large global pharmaceutical company Pressreleaser Ladda ner | Visa Stäng
2023-11-21 Redeye Redeye: Nanexa Q3 - Focused approach Pressreleaser Ladda ner | Visa Stäng
2023-11-21 Emergers Emergers: Equity Research | NANEXA: Raising our LOAs following a review of the projects Pressreleaser Ladda ner | Visa Stäng
2023-11-20 Nanexa Nanexa publishes interim report for January – September 2023 Rapporter Ladda ner | Visa Stäng
2023-11-20 Nanexa Nanexa publicerar delårsrapport för januari-september 2023 Rapporter Ladda ner | Visa Stäng
2023-11-14 Nanexa Nanexa presenterade hälsoekonomiska data på internationell kongress Pressreleaser Ladda ner | Visa Stäng
2023-11-14 Nanexa Nanexa presented Health Economical data at international conference Pressreleaser Ladda ner | Visa Stäng
2023-11-01 Emergers Emergers: Equity Research | NANEXA: Outcome of rights issue forces an investor-friendly focus on core projects Pressreleaser Ladda ner | Visa Stäng
2023-10-30 Nanexa Nanexa offentliggör utfall i företrädesemissionen Pressreleaser Ladda ner | Visa Stäng
2023-10-30 Nanexa Nanexa announces outcome of rights issue Pressreleaser Ladda ner | Visa Stäng
2023-10-20 Nanexa Nanexa erhåller ytterligare teckningsförbindelse i pågående företrädesemission Pressreleaser Ladda ner | Visa Stäng
2023-10-20 Nanexa Nanexa receives additional subscription undertaking in the ongoing rights issue Pressreleaser Ladda ner | Visa Stäng
2023-10-11 Nanexa Nanexa publishes EU growth prospectus in connection with rights issue Pressreleaser Ladda ner | Visa Stäng
2023-10-11 Nanexa Nanexa offentliggör EU-tillväxtprospekt med anledning av företrädesemission Pressreleaser Ladda ner | Visa Stäng
2023-10-11 Nanexa Nanexa reports preliminary key financial information for the period January-September 2023 Pressreleaser Ladda ner | Visa Stäng
2023-10-11 Nanexa Nanexa rapporterar preliminär finansiell nyckelinformation för perioden januari-september 2023 Pressreleaser Ladda ner | Visa Stäng
2023-10-11 Emergers Emergers: Equity Research | NANEXA: Variable roadmap with emphasis on NEX-22 and potential Novo Nordisk deal Pressreleaser Ladda ner | Visa Stäng
2023-10-05 Nanexa Nanexa completes clinical phase I study with NEX-20 Pressreleaser Ladda ner | Visa Stäng
2023-10-05 Nanexa Nanexa har slutfört den kliniska fas I-studien med NEX-20 Pressreleaser Ladda ner | Visa Stäng
2023-09-28 Nanexa Nanexa bjuder in till investerarmöte 9 oktober i Uppsala Pressreleaser Ladda ner | Visa Stäng
2023-09-28 Nanexa Nanexa invites to investor meeting on October 9th in Uppsala Pressreleaser Ladda ner | Visa Stäng
2023-09-22 Nanexa Invitation to commentary regarding rights issue Pressreleaser Ladda ner | Visa Stäng
2023-09-22 Nanexa Inbjudan till kommentar gällande företrädesemission Pressreleaser Ladda ner | Visa Stäng
2023-09-22 Emergers Emergers: NANEXA: Capital raise to pursue a broad set of opportunities in 2024 and 2025 Pressreleaser Ladda ner | Visa Stäng
2023-09-21 Nanexa Nanexa carries out a rights issue of approximately SEK 121 million Pressreleaser Ladda ner | Visa Stäng
2023-09-21 Nanexa Nanexa genomför en företrädesemission om cirka 121 MSEK Pressreleaser Ladda ner | Visa Stäng
2023-09-06 Nanexa Nanexa presenterar vid ISPOR Europe 2023 Pressreleaser Ladda ner | Visa Stäng
2023-09-06 Nanexa Nanexa presents at ISPOR Europe 2023 Pressreleaser Ladda ner | Visa Stäng
2023-08-30 Nanexa Nanexa beviljas patent i Indien Pressreleaser Ladda ner | Visa Stäng
2023-08-30 Nanexa Nanexa is granted patent in India Pressreleaser Ladda ner | Visa Stäng
2023-08-24 Redeye Redeye: Nanexa Q2 - Solid progress but a capital injection is on the horizon Pressreleaser Ladda ner | Visa Stäng
2023-08-24 Emergers Emergers: Equity Research | NANEXA: Progress with NEX-20 and NEX-22 Amid Rising GLP-1 Interest Pressreleaser Ladda ner | Visa Stäng
2023-08-23 Nanexa Nanexa publicerar delårsrapport för januari-juni 2023 Rapporter Ladda ner | Visa Stäng
2023-08-23 Nanexa Nanexa publishes interim report for January – June 2023 Rapporter Ladda ner | Visa Stäng
2023-08-22 Nanexa Invitation to presentation of Nanexa’s Q2 report 2023 Pressreleaser Ladda ner | Visa Stäng
2023-08-22 Nanexa Inbjudan till presentation av Nanexas Q2-rapport 2023 Pressreleaser Ladda ner | Visa Stäng
2023-08-22 Nanexa Nanexa bekräftar fortsatt positiva resultat från en ny preklinisk studie av NEX-22 Pressreleaser Ladda ner | Visa Stäng
2023-08-22 Nanexa Nanexa confirms continued positive results from a new preclinical study of NEX-22 Pressreleaser Ladda ner | Visa Stäng
2023-08-22 Nanexa Nanexa obtains pharmacokinetic data from the NEX-20 Phase 1 study confirming controlled release of lenalidomide Pressreleaser Ladda ner | Visa Stäng
2023-08-22 Nanexa Nanexa erhåller farmakokinetiska data från den kliniska fas I-studien med NEX-20 som konfirmerar kontrollerad frisättning av lenalidomid Pressreleaser Ladda ner | Visa Stäng
2023-07-10 Nanexa Summer letter from Nanexa Pressreleaser Ladda ner | Visa Stäng
2023-07-10 Nanexa Sommarbrev från Nanexa Pressreleaser Ladda ner | Visa Stäng

Kommande händelser

19 Feb 2025 | Bokslutskommuniké 2024